Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Shares of Gilead Sciences Inc. GILD rallied 1.52% to $92.38 Wednesday, on what proved to be an all-around great trading ...

Shares of Gilead Sciences Inc. GILD inched 0.07% higher to $89.94 Monday, on what proved to be an all-around positive trading ...

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where ...

Park Avenue Securities LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 31.4% during the ...

Over the past month, shares of this HIV and hepatitis C drugmaker have returned +1.9%, compared to the Zacks S&P 500 composite's -3.3% change. During this period, the Zacks Medical - Biomedical and ...

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

Morgan Stanley has recently raised Gilead Sciences Inc (GILD) stock rating, as announced on January 10, 2025, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the stock ...

Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...